1 * Hamid Reza Edraki and 2 Safora Ghazimorad
1
Neuroradiologist (LMU Munich -Germany), Faculty
member of Shahid Beheshti University of Medical Sciences,
Tehran, Iran.
2
Master’s degree in psychology, a member of the Iranian
Psychological System Organization, a member of the Iranian Neuropsychological Association and APA,
The providing and editing of the national rare diseases document is one of the most vital activities of the Rare Diseases Foundation, and in this regard, the Rare Diseases Foundation of Iran, with a lot of endeavor and follow-up, and with the participation and cooperation of the professors and expertise of the Foundation and other universities of medical sciences, prepared and compiled the National Document of Rare Diseases of Iran, which after being approved by the Secretariat of the Supreme Council of Health and Food Safety and the cooperation and collaboration of the honorable officials of that ministry and other related institutions, was finally approved by the honorable president and announced. Undoubtedly, the declaration of this document can be a very huge and effective step in determining the duties of the institutions and beneficiaries related to these patients, providing services to rare patients and their families, and solving the problems of these patient respectfully
The deputy of insurance and services of the iran health insurance organization declared :we cover one million and thousand patients in the fund for rare and hard treatment diseases.
In report of mehr news agency ,Mehdi rezaei,
According the insurance coverage of rare and hard treatment patients, announce : 1,600 billion tomans have been paid in the first 4 months of this year to cover the costs of rare and hard treatment patients .
Most of services are provided in the pharmaceutical, medical radiation and laboratory services, 75% of which are related to the pharmaceutical sector .
Rezaei added: 63 service packages have been prepared in this fund for these patients, who have received the most services in the rare and hard treatment patients fund, respectively , for cancer , MS, AND HEMOPHILIA
Annual Meeting Abstract, J Immunol Tech Infect Dis Vol: 7 Issue: 2
Hamid Reza Edraki
Rare Diseases Foundation of Iran (RADOIR)
*Corresponding Author : Dr. Hamid Reza Edraki Rare Diseases Foundation of Iran (RADOIR), Iran Tel: +98-912-130-1258, E-mail: dredraki@gmail.com
Received: August 16, 2018 Accepted: September 27, 2018 Published: October 01, 2018
Citation: Edraki HR (2018) Fetal MRI in Early Diagnosis of Rare Disease in Brain. J Immunol Tech Infect Dis 7:2. doi: 10.4172/2329-9541.1000163
Abstract
A practical hands-on approach for using MRI techniques is provided to promote further fetal pathological conditions. This method of prenatal MRI diagnosis is done through the available literature revision. Apart from the findings and artifacts and numerous high-quality illustrations, the implications of fetal MRI based on medico-legal and ethical viewpoints has increased significantly
Keywords: Rare Diseases; Fetal MRI; Brain; Placenta
Author: Dr. Hamid Reza EDRAKI
Managing Director at Rare Diseases Foundation of Iran (RADOIR)
The state of medical imaging in detecting COVID-19 patients is of high value. The CT scan without contrast media injection as the proposed method in diagnosis during treatment. In some cases, HRCT of lung references is recommended for higher penetration and finer levels, but epidemic and pandemic as well as the high range of X-ray exposition, applying the same method is to be investigated.
The most common sign and symptom of COVID-19 will be ground glass opacity (GGO) of lowers lobes of lungs and specially posterior and lateral segments in lungs in neighboring of chest thoracic wall or pleural cavity which is usually observed 5 days after disease appearance. Since the volumetric mass of the virus is very high and penetrates in lower areas and ends up to infectious and inflammatory changes.
Apart from this important symptom, there are other signs as haziness, consolidation, fibrotic band, crazy paving, speculation of the lesion.
In COVID-19 patients, the pleural effusion or lymphadenopathy are rare, active haziness of developed lobar will turn into bronchopneumonia and interstitial pneumonia which are finally called as white lung.
The simple lung CT scan and not HRCT, the amount of radiation and shorter time left to HRCT. In some centers, 3D methods are also used which are of more value rather than 2D’s. During CT scan, the patient takes a deep breath (deep inhale) and keeps till the end of test and delicate axial cuts later on. The simple radiography of lungs (even digital) is of no value in diagnostic pulmonary involvement with COVID-19.
In the following table, the diagnostic protocol of COVID-19 in CT scan confirmed by The Radiological Society of North America (RSNA) and National Institute of Health (NIH), has been presented.
Rare Diseases Europe, an alliance of over 800 rare disease patient organisations, is today urging Member States of the EU to take off the table the proposal of the Presidency of the EU Council to withdraw Article 7 of the current proposal for European cooperation on health technology assessment (HTA).
Research Article By Dr. H. R. Edraki, RADOIR’s Managing Director: “ Fetal MRI in Early Diagnosis in Brain Disorders” Published By MRI International Book.
By Ed Miseta, Chief Editor, Clinical Leader
Patient recruitment has always been challenge for companies conducting clinical trials. Knowing how to properly engage with advocacy groups can determine whether they will treat you as a trusted partner or a necessary evil.
Using both CRISPR-Cas9 and base editor 3 (BE3) gene-editing tools, the team reduced cholesterol levels in healthy mice treated in utero by targeting a gene that regulates those levels. Also used prenatal gene editing to improve liver function and prevent neonatal death in a subgroup of mice that had been engineered with a mutation causing the lethal liver disease hereditary tyrosinemia type 1 (HT1).